Why the study?
Does intravenous glucagon affect coronary blood flow and myocardial oxygen consumption in humans and dogs?
Does intravenous glucagon affect coronary blood flow and myocardial oxygen consumption in humans and dogs?
Intravenous glucagon acts as a secondary coronary vasodilator, increasing coronary blood flow and myocardial oxygen consumption in both humans and dogs.
Answers are grounded in this paper and cite their sources.
May increase myocardial O2 demand in ischemia; leaves open any therapeutic role in modern cardiac care.
The effects of intravenous administration of glucagon (50 µg/kg) on left coronary blood flow and myocardial oxygen consumption were studied in nine patients during diagnostic cardiac catheterization and in six open-chested anesthetized dogs. Coronary blood flow was measured with the 133 Xe washout technic in man, and with an electromagnetic flowmeter placed around the left anterior descending coronary artery in the dogs. In the patients, glucagon produced a 31% increase in coronary blood flow and a 29% increase in myocardial oxygen consumption, with no change in coronary arteriovenous (A-V) O 2 difference across the heart. In the dogs glucagon produced a 114% increase in coronary blood flow and a 131% increase in myocardial oxygen consumption, again with no change in coronary A-V O 2 difference. Thus glucagon is a secondary coronary vasodilator in both man and dog. The modest chronotropic and inotropic effects of glucagon observed in man were only half as great as those observed in the dog. Part or all of this difference in dose-response relationship between the two species may be related to the different experimental conditions of the study.
No takes yet. Share an insight, caveat, or question.
Manchester et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: